| GC36161-100mg |
|
611168-24-2 |
|
0 |
C33H38O6 |
|
|
|
| GC36161-50mg |
|
611168-24-2 |
|
0 |
C33H38O6 |
|
|
|
| GC36161-10mg |
|
611168-24-2 |
|
0 |
C33H38O6 |
|
|
|
| GC36161-10mM (in 1mL DMSO) |
|
611168-24-2 |
|
0 |
C33H38O6 |
|
|
|
| GC36160-10mg |
|
128400-55-5 |
|
0 |
C46H73ClN4O9 |
|
|
|
| GC36160-5mg |
|
128400-55-5 |
|
0 |
C46H73ClN4O9 |
|
|
|
| GC36160-1mg |
|
128400-55-5 |
|
0 |
C46H73ClN4O9 |
|
|
|
| GC36159-5mg |
|
17989-41-2 |
|
0 |
C3H9O6P |
|
|
|
| GC36159-1mg |
|
17989-41-2 |
|
0 |
C3H9O6P |
|
|
|
| GC36159-10mM (in 1mL DMSO) |
|
17989-41-2 |
|
0 |
C3H9O6P |
|
|
|
| GC36158-100mL |
|
56-81-5 |
|
0 |
C3H8O3 |
|
|
|
| GC36154-5mg |
|
494-08-6 |
|
0 |
C14H18O8 |
|
|
|
| GC36153-50mg |
|
382607-78-5 |
Glucose-conjugated MGMT inhibitor
|
0 |
C24H34BrN5O7S |
|
|
|
| GC36153-10mg |
|
382607-78-5 |
Glucose-conjugated MGMT inhibitor
|
0 |
C24H34BrN5O7S |
|
|
|
| GC36153-5mg |
|
382607-78-5 |
Glucose-conjugated MGMT inhibitor
|
0 |
C24H34BrN5O7S |
|
|
|
| GC36153-10mM (in 1mL DMSO) |
|
382607-78-5 |
Glucose-conjugated MGMT inhibitor
|
0 |
C24H34BrN5O7S |
|
|
|
| GC36152-1mg |
|
— |
Glucagon-like peptide 1 (1-37), human (TFA)
|
0 |
C2HF3O2 |
|
|
|
| GC36150-5mg |
|
107444-51-9 |
Glucagon-Like Peptide (GLP) I (7-36), amide, human
|
0 |
C149H226N40O45 |
|
|
|
| GC36150-1mg |
|
107444-51-9 |
Glucagon-Like Peptide (GLP) I (7-36), amide, human
|
0 |
C149H226N40O45 |
|
|
|
| GC36150-500μg |
|
107444-51-9 |
Glucagon-Like Peptide (GLP) I (7-36), amide, human
|
0 |
C149H226N40O45 |
|
|
|
